Actively Recruiting
Development of Patient Derived Xenografts PDX in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy
Led by Mayo Clinic · Updated on 2026-03-03
999
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Breast cancer patients who still have cancer after neoadjuvant systemic therapy face a high risk of serious recurrence and death. This research aims to collect blood and leftover surgical tissue from these patients to better understand the remaining cancer. The study focuses on growing patient-derived xenografts PDX from surgical tissue to investigate how this cancer may differ and how future treatments might be developed. The study collects blood and tissue samples after chemotherapy or endocrine therapy is completed. These samples will be used to create PDX and organoids in the lab, which help explore new drugs, drug combinations, and mechanisms of treatment resistance. Blood samples will also be analyzed to measure biomarkers like cell-free DNA, circulating tumor cells, and immune cell subpopulations. Participants will provide blood and leftover tissue at the time of surgery. Researchers will monitor outcomes such as generating PDX models and studying immune responses for up to 20 years or until death. This long-term follow-up will help identify new ways to treat breast cancer patients who have residual disease after therapy.
CONDITIONS
Brief Title
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy
- Surgically removable disease after neoadjuvant systemic treatment
- Received at least 2 weeks of neoadjuvant endocrine therapy or at least 2 months of neoadjuvant chemotherapy with signs of residual disease
- Began neoadjuvant chemotherapy or endocrine therapy but stopped due to progressive disease seen on MRI, ultrasound, or physical exam
- Provided written informed consent
- Willing to return for breast cancer surgery
- Willing to provide mandatory blood specimens for research
- Willing to provide mandatory tissue specimens for research and generation of PDX and organoids
You will not qualify if you...
- Not eligible for surgery
- History of prior malignancy within 3 years before registration, except for non-melanoma skin cancer, papillary thyroid cancer, or non-invasive cancers such as carcinoma in situ of the cervix
Research Team
C
Clinical Trials Referral Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here